Japan provides aid as Zimbabwe cholera crisis continues
This article was originally published in Scrip
Executive Summary
Japan has pledged emergency grant aid of $1.5 million to help tackle Zimbabwe's continued cholera crisis. Provided through UNICEF, the aid is expected to help nearly 600,000 people in the next six months, providing water purification chemicals and health education. Other countries providing funding include China ($500,000), Sweden ($2.5 million) and the Netherlands ($11.7 million). Tanzania has provided 41.5 tonnes of drugs, vaccines and water purification chemicals, Namibia $200,000 worth of drugs and medical equipment, and Venezuela 18.5 tonnes of drugs and 10.8 tonnes of water purification tablets, the Zimbabwe newspaper The Herald reports.
You may also be interested in...
How to leverage India: Five up-and-coming domestic players
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
Active Biotech appoints CSO
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed appoints new chief commercial officer
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).